Autopsy findings in patients after curative esophagectomy for esophageal carcinoma

被引:44
作者
Katayama, A
Mahme, K
Tanaka, Y
Takubo, K
Makuuchi, M
Kaminishi, M
机构
[1] Univ Tokyo, Grad Sch Med, Dept Gastrointestinal Oncol, Tokyo, Japan
[2] Saitama Canc Ctr, Dept Surg, Ina, Saitama, Japan
[3] Tokyo Metropolitan Inst Gerontol, Div Clin Pathol, Tokyo, Japan
关键词
D O I
10.1016/S1072-7515(03)00116-9
中图分类号
R61 [外科手术学];
学科分类号
摘要
BACKGROUND: The mode of recurrence after esophagectomy for esophageal cancer has seldom been studied in detail from autopsy findings. STUDY DESIGN: We reviewed the autopsy findings in 43 curatively resected cases of esophageal cancer between 1976 and 1997 at a single institution. RESULTS: Recurrent or residual esophageal cancer was identified in 27 of the 43 patients (62.8%) at autopsy. Local recurrence, lymph node metastases, hematogenous metastases, and serosal carcinomatosis were observed in 11 (25.6%), 18 (41.9%), 17 (39.5%), and I I patients (25.6%), respectively. Metastases to the thoracic, abdominal, and cervical nodes were observed in 37.2%, 16.3%, and 11.6% of the cases at autopsy, respectively. The pulmonary hilar nodes were most frequently involved (25.6%). The frequency of local recurrence was significantly lower in cases after curative subtotal esophagectomy with two- or three-field dissection (19.4%) than in cases after lower esophagectomy (66.7%) (p = 0.032). The frequency of hematogenous metastases after curative esophagectomy after preoperative radiotherapy was significantly lower in responders (Grades 2 to 3) than in nonresponders (Grades 0 to 1) (p = 0.035). CONCLUSIONS: This study showed the characteristics of recurrence after esophagectomy for esophageal cancer. Despite esophagectomy with lymph node dissection, the frequency of each mode of recurrence was remarkably high. Anatomic difficulty of complete removal of lymph nodes by surgical procedures was suggested. Hematogenous metastases and serosal carcinomatosis were beyond surgical resection. More effective multimodal therapy will be required to improve survival of esophageal cancer patients. (C) 2003 by the American College of Surgeons.
引用
收藏
页码:866 / 873
页数:8
相关论文
共 13 条
[1]  
ANDERSON LL, 1982, CANCER, V50, P1587, DOI 10.1002/1097-0142(19821015)50:8<1587::AID-CNCR2820500820>3.0.CO
[2]  
2-S
[3]  
APPELQVIST P, 1975, ANN CLIN RES, V7, P334
[4]  
Fujita H, 1984, Nihon Geka Gakkai Zasshi, V85, P17
[5]  
*JAP SOC ES DIS, 1999, GUID CLIN PATH STUD
[6]  
Mafune K, 1987, Nihon Gan Chiryo Gakkai Shi, V22, P2175
[7]  
Mafune K, 2000, J SURG ONCOL, V74, P196, DOI 10.1002/1096-9098(200007)74:3<196::AID-JSO7>3.3.CO
[8]  
2-F
[9]  
MANDARD AM, 1981, CANCER, V48, P329, DOI 10.1002/1097-0142(19810715)48:2<329::AID-CNCR2820480219>3.0.CO
[10]  
2-V